Evaluation of acellular pertussis vaccine: comparisons among different strains of mice
Open Access
- 17 March 2023
- journal article
- research article
- Published by Taylor & Francis Ltd in Emerging Microbes & Infections
- Vol. 12 (1), e2192822
- https://doi.org/10.1080/22221751.2023.2192822
Abstract
The current study was designed to comparatively analyze the reactions of different mouse strains in response to acellular pertussis(aP) vaccine, with attempt to further provide a reference for aP vaccine evaluation. NIH mice, ICR mice, and BALB/c mice adopted from different pharmacopoeias and studies were utilized to measure the immune protection and immunogenicity of the same batch of aP vaccine according to the MICA from some Asian pharmacopoeias and the pertussis serological potency test (PTST) method from European Pharmacopoeia. Based on our results, the aP vaccine detected by NIH mice had the best potency. So the NIH mice were more suitable for detecting the immune protection of aP vaccine by the Modified intracerebral challenge assay (MICA)method. Given that the levels of PT-IgG and FHA-IgG antibodies in ICR mice were the highest, and the levels of Th1 and Th2 cells were significantly increased (P < 0.01), it was more suitable for the detection of immunogenicity of aP vaccine by PSPT method. Spleen lymphocytes were stimulated by PT and FHA. And the levels of IL-4 in ICR mice and NIH mice were significantly increased, so were the levels of IL-17, IL-23, IL-27, and TNF-α in BALB/c mice. NIH mice have stronger adaptive immunity and the weakest inflammatory response, and ICR mice have enhanced adaptive immunity and inflammatory responses, both of which can be thereby used for evaluation by different pharmacopoeia methods. NIH was more suitable for the MICA method of Chinese Pharmacopoeia, and ICR for the PSPT method of European Pharmacopoeia.Keywords
Funding Information
- National Science and Technology Major Project (2017ZX10304402-002)
This publication has 34 references indexed in Scilit:
- Susceptibility to Plasmodium yoelii Preerythrocytic Infection in BALB/c Substrains Is Determined at the Point of Hepatocyte InvasionInfection and Immunity, 2015
- Relationship of immunogenicity to protective potency in acellular pertussis vaccinesHuman Vaccines & Immunotherapeutics, 2014
- Characterization of Outer Membrane Vesicles fromBrucella melitensisand Protection Induced in MiceJournal of Immunology Research, 2011
- Synergic Effect of Genotype Changes in Pertussis Toxin and Pertactin on Adaptation to an Acellular Pertussis Vaccine in the Murine Intranasal Challenge ModelClinical and Vaccine Immunology, 2010
- Modified intra-cerebral challenge assay for acellular pertussis vaccines: Comparisons among whole cell and acellular vaccinesVaccine, 2009
- BALB/c mice genetically susceptible to proteoglycan-induced arthritis and spondylitis show colony-dependent differences in disease penetranceArthritis Research & Therapy, 2009
- WHO Working Group meeting on standardization of acellular pertussis vaccines: Potency assay: Beijing, China, 7–9 November 2007Vaccine, 2008
- The Pertussis Serological Potency Test Collaborative Study to Evaluate Replacement of the Mouse Protection TestBiologicals, 2000
- Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccinesVaccine, 1999
- Seasonal Incidence of Whooping Cough in the United StatesAmerican Journal of Public Health and the Nations Health, 1932